退缩
发表于 2025-3-21 18:03:58
书目名称Evidence-Based Pharmacovigilance影响因子(影响力)<br> http://impactfactor.cn/if/?ISSN=BK0317560<br><br> <br><br>书目名称Evidence-Based Pharmacovigilance影响因子(影响力)学科排名<br> http://impactfactor.cn/ifr/?ISSN=BK0317560<br><br> <br><br>书目名称Evidence-Based Pharmacovigilance网络公开度<br> http://impactfactor.cn/at/?ISSN=BK0317560<br><br> <br><br>书目名称Evidence-Based Pharmacovigilance网络公开度学科排名<br> http://impactfactor.cn/atr/?ISSN=BK0317560<br><br> <br><br>书目名称Evidence-Based Pharmacovigilance被引频次<br> http://impactfactor.cn/tc/?ISSN=BK0317560<br><br> <br><br>书目名称Evidence-Based Pharmacovigilance被引频次学科排名<br> http://impactfactor.cn/tcr/?ISSN=BK0317560<br><br> <br><br>书目名称Evidence-Based Pharmacovigilance年度引用<br> http://impactfactor.cn/ii/?ISSN=BK0317560<br><br> <br><br>书目名称Evidence-Based Pharmacovigilance年度引用学科排名<br> http://impactfactor.cn/iir/?ISSN=BK0317560<br><br> <br><br>书目名称Evidence-Based Pharmacovigilance读者反馈<br> http://impactfactor.cn/5y/?ISSN=BK0317560<br><br> <br><br>书目名称Evidence-Based Pharmacovigilance读者反馈学科排名<br> http://impactfactor.cn/5yr/?ISSN=BK0317560<br><br> <br><br>
止痛药
发表于 2025-3-21 23:21:57
http://reply.papertrans.cn/32/3176/317560/317560_2.png
placebo-effect
发表于 2025-3-22 02:47:15
http://reply.papertrans.cn/32/3176/317560/317560_3.png
要素
发表于 2025-3-22 06:30:28
Pediatric Pharmacovigilance: Current Practice and Future Perspectives,ype, suspected medicines, age and gender of the child, and type of reporter. Secondly to review experiences with the EU pediatric regulation and its impact on the conduction of pediatric clinical trials in Europe. This literature review showed that occurrence of ADRs in pediatric populations differs
Insensate
发表于 2025-3-22 12:43:23
Detecting Safety Issues in Clinical Trials, is collected and often undergoes a detailed review by the sponsor. Detecting safety issues during a trial has revolved primarily around the Data Safety Monitoring Board (DSMB) who review unblinded summarized data and case reports. Final trial publications typically contain descriptive analyses on t
Flatus
发表于 2025-3-22 12:55:06
Developments and Future Directions of Prescription-Based Observational Cohort Pharmacovigilance,development as compared to during use within routine clinical practice, post marketing. Changes in pharmacovigilance regulations and legislation have given greater weight to the importance of post-marketing observational research and understanding more regarding natural variation in patients and the
Flatus
发表于 2025-3-22 18:44:24
Electronic Health Record, Transactional Insurance Claims, and Distributed Databases in Pharmacovigith record databases, traditional insurance claims databases, and distributed data networks. Strengths, weaknesses, considerations, and examples are presented. Finally, the chapter covers the concepts and challenges of data linkage across resources and offers several future perspectives on data avail
缓解
发表于 2025-3-23 00:08:58
http://reply.papertrans.cn/32/3176/317560/317560_8.png
evasive
发表于 2025-3-23 04:30:03
Patient Reported Outcomes in Pharmacovigilance,first hand from those who have experienced the adverse drug reactions. These experiences are richer in context and information of the impact of an ADR as compared to information from healthcare professionals. New technologies (i.e., Internet) have made the collection of patient reported information
巨硕
发表于 2025-3-23 08:27:46
Evidence-Based Pharmacovigilance for Medicines Used in Public Health Programs in Africa,me for International Drug Monitoring having increased from just 5 in the year 2000 to 35 in 2017. However, published information indicates that Africa’s contribution of individual case safety reports (ICSRs) to the WHO ICSR database (VigiBase) is paltry currently standing at less than 1% of the >14